Commitments and Contingencies (Details) - USD ($)					3 Months Ended	12 Months Ended
	Jul. 01, 2024	Apr. 03, 2024	Apr. 01, 2024	Oct. 18, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies [Line Items]
Reimbursement of legal costs					$ 1,250,000	$ 1,250,000
Several liability				$ 14,684,833
Net sales of epoladerm				5.00%
Net sales of envelta				7.50%
Potential damages				$ 13,400,000
Potential damages						$ 6,700,000
Proffered documents (in Shares)						1,182
Several liability						$ 28,382
Royalties annual net sales percentage						6.00%
Accrued litigation						$ 6,000,000	$ 2,000,000
General and administrative expense						$ 10,572,181	11,082,463
Minimum [Member]
Commitments and Contingencies [Line Items]
Net sales of probudur				8.00%
Development of epoladerm						18 months
Royalty rate						1.00%
Maximum [Member]
Commitments and Contingencies [Line Items]
Net sales of probudur				11.00%
Development of epoladerm						27 days
Royalty rate						3.00%
Settlement Agreement [Member]
Commitments and Contingencies [Line Items]
General and administrative expense						$ 4,000,000	$ 2,000,000
Mr Mack and Virpax [Member]
Commitments and Contingencies [Line Items]
Potential damages				$ 6,700,000
Anthony P Mack [Member]
Commitments and Contingencies [Line Items]
Annual salary						$ 711,000
Forecast [Member]
Commitments and Contingencies [Line Items]
Litigation settlement	$ 2,500,000	$ 3,500,000	$ 6,000,000
Misuse of Scilex [Member]
Commitments and Contingencies [Line Items]
Potential damages				$ 1,300,000